Yes, CD25 can be targeted for cancer therapy. Several strategies are being explored to inhibit CD25 and deplete Tregs in the tumor microenvironment, thereby enhancing anti-tumor immunity. One approach involves the use of monoclonal antibodies designed to bind to CD25 and either block its function or induce the depletion of Tregs. Some of these antibodies are currently being evaluated in clinical trials.
